Type 2 diabetes patients need clear blood pressure targets. Doctors worry low pressure might harm them. The study published in the Journal of the American College of Cardiology reviewed all major research. They searched PubMed, Embase, and Web of Science until November 30, 2024. They found 89 cohorts from 113 articles. These included 5,875,364 diabetes patients. Researchers used one-stage mixed-effects dose-response meta-analysis. They examined all-cause mortality first. SBP showed J-shaped curve with all-cause death. DBP also showed J-shape for mortality. Cardiovascular events followed similar SBP pattern. Risks flattened at lower BP levels.
Lower SBP Safe After Confounding Adjustment
Studies with baseline heart disease or cancer patients showed different results. When researchers removed these groups, findings changed. Low SBP linked to lower cardiovascular event risk. All-cause mortality risk flattened instead of rising. This suggests reverse causation explained prior J-curves. Sick patients naturally have lower pressure before death.
Renal Risk Rises Linearly with BP
Kidney outcomes showed different patterns. Renal events increased steadily with higher BP. Estimated glomerular filtration rate decline followed linear trend. Albuminuria development and progression showed monotonic risk. No J-shape appeared for kidney complications.
Intensive BP Control Justified in Diabetes
Endocrinologists can confidently target SBP below 120 mmHg in type 2 diabetes. Cardiovascular protection outweighs theoretical mortality concerns. Renal risk reduction follows linear pattern favoring aggressive control. Routine monitoring prevents orthostatic hypotension during titration. SGLT2 inhibitors and GLP1 agonists provide synergistic pressure lowering. Combination therapy safely achieves multifactorial risk reduction maximizing event-free survival across diabetes lifespan.
Clinical Practice Changes Expected
Guidelines should update BP targets reflecting meta-analysis findings. Annual ambulatory monitoring optimizes titration safety. Home pressure tracking engages motivated patients. Frailty assessment guides individualized lower limits. Shared decision making incorporates absolute risk reduction data.